A record of what Daljeet Kohli said publicly, with the source. Not advice.
Pending — not yet graded
“Bullish on the pharma sector, expecting strong performance over the next one to two years. Specifically highlights CDMO, CMO, and CRMO companies as major beneficiaries due to increased activity ahead of the US Biosecure Act, despite its 2032 applicability.”
Nifty PharmaBullishCalled 30 Oct 2024
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Daljeet Kohli’s full track record